The Effects of ELND005 (Scyllo-Inositol) on Emergence of Neuropsychiatric Symptoms (NPS) in Mild/Moderate Alzheimer's Disease: Results from a 78-Week Phase 2 Study (P04.215)

Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. P04.215-P04.215 ◽  
Author(s):  
P. Tariot ◽  
C. Lyketsos ◽  
G. Crans ◽  
J. Cedarbaum ◽  
C. Hernandez ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neuropsychiatric Symptoms ◽  
Phase 2 ◽  
Phase 2 Study

scholarly journals ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Nature Aging ◽  
2021 ◽  
Vol 1 (6) ◽  
pp. 521-534
Author(s):  
Petr Novak ◽  
Branislav Kovacech ◽  
Stanislav Katina ◽  
Reinhold Schmidt ◽  
Philip Scheltens ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Active Immunotherapy ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Randomized Phase 2

scholarly journals New approaches to symptomatic treatments for Alzheimer’s disease

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Jeffrey Cummings
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neuropsychiatric Symptoms ◽  
Symptomatic Treatment ◽  
Phase 2 ◽  
Phase 3 ◽  
Trial Conduct ◽  
Outcomes Measures ◽  
New Treatments ◽  
And Behavior

Abstract Background Successful development of agents that improve cognition and behavior in Alzheimer’s disease (AD) is critical to improving the lives of patients manifesting the symptoms of this progressive disorder. Discussion There have been no recent approvals of cognitive enhancing agents for AD. There are currently 6 cognitive enhancers in Phase 2 trials and 4 in phase 3. They represent a variety of novel mechanisms. There has been progress in developing new treatments for neuropsychiatric symptoms in AD with advances in treatment of insomnia, psychosis, apathy, and agitation in AD. There are currently 4 AD-related psychotropic agents in Phase 2 trials and 7 in Phase 3 trials. Many novel mechanisms are being explored for the treatment of cognitive and behavioral targets. Progress in trial designs, outcomes measures, and population definitions are improving trial conduct for symptomatic treatment of AD. Conclusions Advances in developing new agents for cognitive and behavioral symptoms of AD combined with enhanced trial methods promise to address the unmet needs of patients with AD for improved cognition and amelioration of neuropsychiatric symptoms.

Sign in / Sign up

Export Citation Format

Share Document